Literature DB >> 6334138

Use of interleukin-2 in patients with acquired immunodeficiency syndrome.

H C Lane, J P Siegel, A H Rook, H Masur, E P Gelmann, G V Quinnan, A S Fauci.   

Abstract

Twelve patients with acquired immunodeficiency syndrome were treated with a natural product, highly purified human interleukin-2. Doses ranged from 250 to 250,000 units. No clinical responses were seen. Minimal toxicity was noted and consisted of mild prolongation of partial thromboplastin time and proteinuria. Immunologic changes during the study included a decrease in the number of circulating T8 lymphocytes, increased skin test reactivity, and a decline in serum immunoglobulin levels.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Americas; Clinical Research; Developed Countries; Developing Countries; Diseases; Hematological Effects; Hiv Infections; Immunoglobulin Alterations; Immunological Effects; North America; Northern America; Research Methodology; Treatment; United States; Viral Diseases

Mesh：

Substances：

Year:  1984        PMID： 6334138

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN： 0732-6580


  10 in total

Review 1.  Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.

Authors:  P De Paoli
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

2.  Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals.

Authors:  P N Nehete; P C Johnson; S J Schapiro; R B Arlinghaus; K J Sastry
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

3.  Induction of HIV-1 replication by type 1-like cytokines, interleukin (IL)-12 and IL-15: effect on viral transcriptional activation, cellular proliferation, and endogenous cytokine production.

Authors:  L Al-Harthi; K A Roebuck; A Landay
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

Review 4.  The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.

Authors:  S D Voss; G Weil-Hillman; J A Hank; J A Sosman; P M Sondel
Journal:  Bull N Y Acad Med       Date:  1989-01

5.  In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).

Authors:  N Saijo; A Ozaki; H Nakano; M Sakurai; H Takahashi; Y Sasaki; A Hoshi
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 6.  Lymphokines. Progress and promise.

Authors:  D W Horohov; J P Siegel
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 7.  Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.

Authors:  A Kinter; A S Fauci
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

8.  In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon.

Authors:  S M Hammer; J M Gillis; J E Groopman; R M Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.

Authors:  H Teppler; G Kaplan; K A Smith; A L Montana; P Meyn; Z A Cohn
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients.

Authors:  J Chehimi; S E Starr; I Frank; M Rengaraju; S J Jackson; C Llanes; M Kobayashi; B Perussia; D Young; E Nickbarg
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.